Network based biomarkers in Alzheimer's disease: review and future directions

By 2050 it is estimated that the number of worldwide Alzheimer’s (AD) patients will quadruple from the current number of 36 million people. To date, no single test, prior to postmortem examination, can confirm that a person suffers from AD. Therefore, there is a strong need for accurate and sensitiv...

Full description

Bibliographic Details
Main Authors: Jaime eGomez-Ramirez, Jinglong eWu
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-02-01
Series:Frontiers in Aging Neuroscience
Subjects:
AD
Online Access:http://journal.frontiersin.org/Journal/10.3389/fnagi.2014.00012/full
id doaj-856c1aa55eab4fa2a9d953ac5e778f91
record_format Article
spelling doaj-856c1aa55eab4fa2a9d953ac5e778f912020-11-24T22:57:03ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652014-02-01610.3389/fnagi.2014.0001275530Network based biomarkers in Alzheimer's disease: review and future directionsJaime eGomez-Ramirez0Jaime eGomez-Ramirez1Jinglong eWu2Universidad Politécnica de MadridOkayama UniversityOkayama UniversityBy 2050 it is estimated that the number of worldwide Alzheimer’s (AD) patients will quadruple from the current number of 36 million people. To date, no single test, prior to postmortem examination, can confirm that a person suffers from AD. Therefore, there is a strong need for accurate and sensitive tools for the early diagnoses of AD. The complex etiology and multiple pathogenesis of AD calls for a system-level understanding of the currently available biomarkers and the study of new biomarkers via network-based modeling of heterogeneous data types. In this review, we summarize recent research on the study of AD as a connectivity syndrome. We argue that a network-based approach in biomarker discovery, will provide key insights to fully understand the network degeneration hypothesis (disease starts in specific network areas and progressively spreads to connected areas of the initial loci-networks) with a potential impact for early diagnosis and disease-modifyig treatments. We introduce a new framework for the quantitative study of biomarkers that can help shorten the transition between academic research and clinical diagnosis in AD.http://journal.frontiersin.org/Journal/10.3389/fnagi.2014.00012/fullDefault Mode Networkpositron emission tomography (PET)amyloid-beta peptideBayesian inferenceModel selectionAD
collection DOAJ
language English
format Article
sources DOAJ
author Jaime eGomez-Ramirez
Jaime eGomez-Ramirez
Jinglong eWu
spellingShingle Jaime eGomez-Ramirez
Jaime eGomez-Ramirez
Jinglong eWu
Network based biomarkers in Alzheimer's disease: review and future directions
Frontiers in Aging Neuroscience
Default Mode Network
positron emission tomography (PET)
amyloid-beta peptide
Bayesian inference
Model selection
AD
author_facet Jaime eGomez-Ramirez
Jaime eGomez-Ramirez
Jinglong eWu
author_sort Jaime eGomez-Ramirez
title Network based biomarkers in Alzheimer's disease: review and future directions
title_short Network based biomarkers in Alzheimer's disease: review and future directions
title_full Network based biomarkers in Alzheimer's disease: review and future directions
title_fullStr Network based biomarkers in Alzheimer's disease: review and future directions
title_full_unstemmed Network based biomarkers in Alzheimer's disease: review and future directions
title_sort network based biomarkers in alzheimer's disease: review and future directions
publisher Frontiers Media S.A.
series Frontiers in Aging Neuroscience
issn 1663-4365
publishDate 2014-02-01
description By 2050 it is estimated that the number of worldwide Alzheimer’s (AD) patients will quadruple from the current number of 36 million people. To date, no single test, prior to postmortem examination, can confirm that a person suffers from AD. Therefore, there is a strong need for accurate and sensitive tools for the early diagnoses of AD. The complex etiology and multiple pathogenesis of AD calls for a system-level understanding of the currently available biomarkers and the study of new biomarkers via network-based modeling of heterogeneous data types. In this review, we summarize recent research on the study of AD as a connectivity syndrome. We argue that a network-based approach in biomarker discovery, will provide key insights to fully understand the network degeneration hypothesis (disease starts in specific network areas and progressively spreads to connected areas of the initial loci-networks) with a potential impact for early diagnosis and disease-modifyig treatments. We introduce a new framework for the quantitative study of biomarkers that can help shorten the transition between academic research and clinical diagnosis in AD.
topic Default Mode Network
positron emission tomography (PET)
amyloid-beta peptide
Bayesian inference
Model selection
AD
url http://journal.frontiersin.org/Journal/10.3389/fnagi.2014.00012/full
work_keys_str_mv AT jaimeegomezramirez networkbasedbiomarkersinalzheimer39sdiseasereviewandfuturedirections
AT jaimeegomezramirez networkbasedbiomarkersinalzheimer39sdiseasereviewandfuturedirections
AT jinglongewu networkbasedbiomarkersinalzheimer39sdiseasereviewandfuturedirections
_version_ 1725652243227607040